结合WEE1抑制剂和维生素K2可提高慢性髓性白血病的治疗效果
Seiichi Okabe1, Yuya Arai1, Akihiko Gotoh1
1Department of Hematology Tokyo Medical University Tokyo Japan.
Cancer innovation
|September 2, 2025
概括
结合WEE1抑制剂MK- 1775与维生素K2 (VK2) 治疗慢性髓性白血病 (CML),包括TKI耐药形式,具有前景. 这种新的方法针对CML细胞,诱导细胞亡并降低活力.
科学领域:
- 癌症学
- 分子生物学
- 药理学
背景情况:
- 慢性髓性白血病 (CML) 是由BCR::ABL1融合基因驱动的,导致ABL氨酸激酶激活和白血病细胞存活.
- 氨酸激酶抑制剂 (TKIs) 是有效的,但耐药性仍然是CML治疗的一个重大挑战.
- 针对BCR:ABL1独立抗性机制的新疗法对于推进CML治疗至关重要.
研究的目的:
- 研究WEE1抑制剂MK-1775和维生素K2 (VK2) 对慢性髓性白血病 (CML) 的联合治疗潜力.
- 分析CML患者的基因和转录表达差异,以了解潜在的机制.
- 评估MK-1775和VK2单独和组合在CML细胞系上的疗效,包括对TKI耐药的变体.
主要方法:
- 从CML患者和健康对照者的mRNA概况进行深度测序.
- 使用RaNA-Seq和Heatmapper进行差异表达分析.
- 评估MK- 1775和VK2对CML细胞活力,细胞亡和线粒体膜潜力的影响.
主要成果:
- 通过卡斯帕酶3/7激活,MK- 1775抑制了标准和TKI耐性CML细胞系的生长和诱导细胞亡.
- 维生素K2 (VK2) 降低了CML细胞活力和增强了细胞毒性.
- 结合MK- 1775和VK2治疗显著降低了殖民地生长,破坏了线粒体膜潜力,增加了CML细胞死亡,包括TKI耐药细胞.
结论:
- MK-1775和VK2的组合显示出作为一种新的CML治疗策略的巨大潜力.
- 这种组合疗法对治疗TCI耐药性CML病例尤为有希望.
- 对这种联合治疗方案的进一步研究可能会改善CML患者的治疗结果.
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Combined Effects of Drugs: Synergism
4.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.7K
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22


